Product Description: 4-MMPB is a selective inhibitor of 15-lipoxygenase, with an IC50 of 18 μM. 4-MMPB has IC50s of 19.5 μM and 19.1 μM for soybean 15-lipoxygenase (SLO) and human 15-lipoxygenase-1 (15-LOX-1), respectively. 4-MMPB has potential for the research of prostate cancer[1][2][3][4].
Applications: COVID-19-immunoregulation
Formula: C16H19N5S
References: [1]Mohsen Nikpour, et al. Synthesis of new series of pyrimido[4,5-b][1,4] benzothiazines as 15-lipoxygenase inhibitors and study of their inhibitory mechanism. 2013, 22(10), 5036-5043./[2]Seyed Jamal Alavi, et al. A novel class of human 15-LOX-1 inhibitors based on 3-hydroxycoumarin. Chem Biol Drug Des. 2018 Jun;91(6):1125-1132./[3]M Bakavoli, et al. Design and synthesis of pyrimido[4,5-b][1,4]benzothiazine derivatives, as potent 15-lipoxygenase inhibitors. Bioorg Med Chem. 2007 Mar 1;15(5):2120-6./[4]Saffiyeh Saboormaleki, et al. 7-Farnesyloxycoumarin Exerts Anti-cancer Effects on a Prostate Cancer Cell Line by 15-LOX-1 Inhibition. Arch Iran Med. 2018 Jun 1;21(6):251-259.
CAS Number: 928853-86-5
Molecular Weight: 313.42
Compound Purity: 98.54
Research Area: Cancer
Solubility: DMSO : 7.69 mg/mL (ultrasonic)
Target: Apoptosis;Lipoxygenase
English
Deutsch
